Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine and Hepatitis Research Center, College of Medicine, Center for Cancer Research and Center for Liquid Biopsy, Kaohsiung Medical University, Kaohsiung, Taiwan.
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
J Formos Med Assoc. 2020 Jun;119(6):1019-1040. doi: 10.1016/j.jfma.2020.04.003. Epub 2020 Apr 29.
Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy, excellent safety profile, and truncated treatment duration, has revolutionized the paradigm of hepatitis C treatment and made HCV elimination possible. To provide timely guidance for optimal hepatitis C management, the Taiwan Association for the Study of the Liver (TASL) established an expert panel to publish a 2-part consensus statement on the management of hepatitis C in the DAA era. After comprehensive literature review and a consensus meeting, patient-oriented, genotype-guided recommendations on hepatitis C treatment for the general and special populations have been provided based on the latest indications and scientific evidence. In the first part of this consensus, we present the epidemiology and treatment situation of hepatitis C in Taiwan, the development of DAA, pre-treatment evaluation, post sustained virologic response (SVR) monitoring, and most importantly the treatment recommendations for the general population with compensated liver disease. The second part will focus on the treatment recommendations for the special populations.
丙型肝炎病毒（HCV）感染仍然是一个主要的公共卫生问题，在台湾的流行率很高。最近，直接作用抗病毒（DAA）药物的出现，具有更高的疗效、出色的安全性和缩短的治疗持续时间，彻底改变了丙型肝炎治疗的模式，并使消除丙型肝炎成为可能。为了为最佳丙型肝炎管理提供及时的指导，台湾肝病研究学会（TASL）成立了一个专家小组，就 DAA 时代丙型肝炎的管理发表了两部分共识声明。经过全面的文献回顾和共识会议，根据最新的适应症和科学证据，为一般人群和特殊人群的丙型肝炎治疗提供了以患者为导向、基于基因型的建议。在本共识的第一部分，我们介绍了台湾丙型肝炎的流行病学和治疗情况、DAA 的发展、治疗前评估、持续病毒学应答（SVR）后的监测，以及最重要的是代偿性肝病一般人群的治疗建议。第二部分将重点介绍特殊人群的治疗建议。
